Page last updated: 2024-10-22

albuterol and Cough

albuterol has been researched along with Cough in 87 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

Excerpt	Relevance	Reference
"The efficacy of a new combination drug containing ambroxol, guaifenesin, and levosalbutamol in the treatment of productive cough in adult patients with acute bronchitis is superior to the efficacy of Ascoril Expectorant."	9.69	[Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch ( Esaulova, NA; Leshchenko, IV; Viktorova, IA; Zaitsev, AA, 2023)
" The aim of this study was to evaluate the effect of albuterol spray on hypoxia and bronchospasm in patients with COPD under general anesthesia."	9.69	The Effect of Albuterol Spray on Hypoxia and Bronchospasm in Patients with Chronic Obstructive Pulmonary Disease (COPD) under General Anesthesia: A bouble-Blind Randomized Clinical Trial. ( Barzegari, A; Maddah, SA, 2023)
" Following iv fentanyl (2 micro g x kg(-1)) the incidence of cough was recorded and graded as mild (1-2), moderate (3-5) and severe (> 5) depending on the number of coughs observed."	9.10	Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. ( Agarwal, A; Ambesh, S; Azim, A; Bose, N; Dhiraj, S; Sahu, D; Singh, U, 2003)
"Fifty-nine non-asthmatic children with acute cough were randomized to receive oral albuterol or placebo for 7 d."	9.09	Is oral albuterol effective for acute cough in non-asthmatic children? ( Bernard, DW; Duggan, AK; Goepp, JG; Rowe, PC; Serwint, JR, 1999)
"We evaluated the effects of smoking history and albuterol treatment on the amplitude and frequency of cough during emergence from anesthesia."	9.08	Cough during emergence from isoflurane anesthesia. ( Bishop, MJ; Kim, ES, 1998)
"Oral albuterol should not be used in unselected patients with acute, nonspecific cough."	9.08	A randomized controlled trial of oral albuterol in acute cough. ( Littenberg, B; Smith, DS; Wheeler, M, 1996)
"Patients treated with albuterol were less likely to be coughing after 7 days of treatment than patients treated with erythromycin (41% vs 88%, P less than ."	9.07	A comparison of albuterol and erythromycin for the treatment of acute bronchitis. ( Hueston, WJ, 1991)
"A double-blind, randomized placebo-controlled trial of albuterol delivered by metered-dose inhaler (MDI) was conducted in a primary care setting with healthy adult patients who presented with a productive cough of fewer than 30 days' duration."	9.07	Albuterol delivered by metered-dose inhaler to treat acute bronchitis. ( Hueston, WJ, 1994)
"The antitussive effects of dextromethorphan (30 mg) + salbutamol (2 mg), dextromethorphan (30 mg) alone and placebo on artificial cough induced by citric acid were compared in 19 healthy non-smoking volunteers in a double-blind crossover study."	9.06	Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. ( Karttunen, P; Kolonen, S; Silvasti, M; Tukiainen, H, 1987)
"The efficacy of an antitussive-beta 2-sympathomimetic combination (dextromethorphan-salbutamol) was compared with that of a plain antitussive (dextromethorphan) and a placebo in a double-blind trial in 108 out-patients with cough associated with acute respiratory infection."	9.06	The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-beta 2-sympathomimetic combination. ( Flygare, U; Karttunen, P; Korhonen, R; Korhonen, T; Majander, R; Seuri, M; Silvasti, M; Tukiainen, H, 1986)
"The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy."	7.71	Lidocaine inhalation for cough suppression. ( Udezue, E, 2001)
"In a complex seven-period cross-over trial to study the effects of a drug in attenuating capsaicin-induced coughing, counts of numbers of coughs were recorded 32 times in each period."	7.71	Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing. ( Jackson, D; Jones, B; Lindsey, JK; Stevens, JW, 2002)
"The efficacy of a new combination drug containing ambroxol, guaifenesin, and levosalbutamol in the treatment of productive cough in adult patients with acute bronchitis is superior to the efficacy of Ascoril Expectorant."	5.69	[Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch ( Esaulova, NA; Leshchenko, IV; Viktorova, IA; Zaitsev, AA, 2023)
" The aim of this study was to evaluate the effect of albuterol spray on hypoxia and bronchospasm in patients with COPD under general anesthesia."	5.69	The Effect of Albuterol Spray on Hypoxia and Bronchospasm in Patients with Chronic Obstructive Pulmonary Disease (COPD) under General Anesthesia: A bouble-Blind Randomized Clinical Trial. ( Barzegari, A; Maddah, SA, 2023)
" Following iv fentanyl (2 micro g x kg(-1)) the incidence of cough was recorded and graded as mild (1-2), moderate (3-5) and severe (> 5) depending on the number of coughs observed."	5.10	Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. ( Agarwal, A; Ambesh, S; Azim, A; Bose, N; Dhiraj, S; Sahu, D; Singh, U, 2003)
"Fifty-nine non-asthmatic children with acute cough were randomized to receive oral albuterol or placebo for 7 d."	5.09	Is oral albuterol effective for acute cough in non-asthmatic children? ( Bernard, DW; Duggan, AK; Goepp, JG; Rowe, PC; Serwint, JR, 1999)
"We evaluated the effects of smoking history and albuterol treatment on the amplitude and frequency of cough during emergence from anesthesia."	5.08	Cough during emergence from isoflurane anesthesia. ( Bishop, MJ; Kim, ES, 1998)
"Oral albuterol should not be used in unselected patients with acute, nonspecific cough."	5.08	A randomized controlled trial of oral albuterol in acute cough. ( Littenberg, B; Smith, DS; Wheeler, M, 1996)
"Patients treated with albuterol were less likely to be coughing after 7 days of treatment than patients treated with erythromycin (41% vs 88%, P less than ."	5.07	A comparison of albuterol and erythromycin for the treatment of acute bronchitis. ( Hueston, WJ, 1991)
"A double-blind, randomized placebo-controlled trial of albuterol delivered by metered-dose inhaler (MDI) was conducted in a primary care setting with healthy adult patients who presented with a productive cough of fewer than 30 days' duration."	5.07	Albuterol delivered by metered-dose inhaler to treat acute bronchitis. ( Hueston, WJ, 1994)
"The antitussive effects of dextromethorphan (30 mg) + salbutamol (2 mg), dextromethorphan (30 mg) alone and placebo on artificial cough induced by citric acid were compared in 19 healthy non-smoking volunteers in a double-blind crossover study."	5.06	Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. ( Karttunen, P; Kolonen, S; Silvasti, M; Tukiainen, H, 1987)
"The efficacy of an antitussive-beta 2-sympathomimetic combination (dextromethorphan-salbutamol) was compared with that of a plain antitussive (dextromethorphan) and a placebo in a double-blind trial in 108 out-patients with cough associated with acute respiratory infection."	5.06	The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-beta 2-sympathomimetic combination. ( Flygare, U; Karttunen, P; Korhonen, R; Korhonen, T; Majander, R; Seuri, M; Silvasti, M; Tukiainen, H, 1986)
"Honey probably relieves cough symptoms to a greater extent than no treatment, diphenhydramine, and placebo, but may make little or no difference compared to dextromethorphan."	4.98	Honey for acute cough in children. ( Meremikwu, MM; Oduwole, O; Oyo-Ita, A; Udoh, EE, 2018)
" Diphenhydramine did not change coughing episodes; the mean difference (MD) of coughing spells per 24 hours was 1."	4.88	Symptomatic treatment of the cough in whooping cough. ( Bettiol, S; Harnden, A; Heneghan, CJ; Perera, R; Roberts, NW; Thompson, MJ; Wang, K, 2012)
" Diphenhydramine did not change coughing episodes; the mean difference of coughing spells per 24 hours was 1."	4.86	Symptomatic treatment of the cough in whooping cough. ( Bettiol, S; Harnden, A; Heneghan, CJ; Perera, R; Roberts, NW; Thompson, MJ, 2010)
"In a complex seven-period cross-over trial to study the effects of a drug in attenuating capsaicin-induced coughing, counts of numbers of coughs were recorded 32 times in each period."	3.71	Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing. ( Jackson, D; Jones, B; Lindsey, JK; Stevens, JW, 2002)
"The purpose of this study was to observe the effectiveness of lidocaine in suppressing cough which is a logical extension of its established use in bronchoscopy."	3.71	Lidocaine inhalation for cough suppression. ( Udezue, E, 2001)
"There was no relationship between the bronchial responsiveness to histamine and acetic acid cough threshold in these patients."	3.69	Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma. ( Mochizuki, H; Morikawa, A; Shimizu, T; Tokuyama, K, 1996)
"Treatments combining acetylcysteine by mouth and beta 2-agonists aerosols were given to 293 coal-miners or ex-coal miners suffering from chronic bronchitis presenting an acute phase of their illness and complaining of an increased sputum production."	3.66	Clinical effects of mucolytics associated with bronchodilators in treating exacerbation of chronic bronchitis in coal miners. ( Minette, A, 1982)
" The added observation that theophylline and salbutamol were effective suggests that the condition is a manifestation of asthma."	3.66	Persistent cough a forme-fruste of asthma. ( Benzaray, S; Katznelson, D; Yahav, Y, 1982)
"Acute bronchiolitis is a common disorder of infants that often results in hospitalization."	2.82	A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants. ( Flores, P; Mendes, AL; Neto, AS, 2016)
"After discontinuation of the treatment, cough scores increased, pulmonary function and eosinophilic airway inflammation were aggravated and returned to the baseline levels."	2.80	Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. ( Kawagoe, M; Kirishi, S; Kondo, M; Kubota, N; Tagaya, E; Tamaoki, J, 2015)
"Post-viral cough is a type of cough originating from upper respiratory tract infections that persists after the infection is resolved."	2.79	A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. ( Del Forno, M; Fabbri, E; Lecchi, M; Mastroroberto, M; Mazzolini, M; Morselli-Labate, AM; Nava, S; Pandolfi, P; Pisani, L; Zanasi, A, 2014)
"Results."	2.79	[Therapeutic modalities for the management of cough associated with acute respiratory viral infection, effective in an otolaryngologist's practice]. ( Korostelev, SA; Mitiuk, AM; Ovchinnikov, AI; Paniakina, MA, 2014)
" Ascoril expectorant caused no adverse reactions and was well tolerated by the patients."	2.78	[Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan]. ( Abuova, GT; An, ÉA; Ermekbaeva, BA; Guliaev, AE; Nurgozhin, TS; Zhaugasheva, SK, 2013)
"The cough is often painful and impairs the quality of life of the patients."	2.77	Inhalation of corticosteroid and β-agonist for persistent cough following pulmonary resection. ( Sawada, S; Suehisa, H; Yamashita, M, 2012)
"Significant cough is the most reliable antecedent of wheezing during an RTI."	2.74	Signs and symptoms that precede wheezing in children with a pattern of moderate-to-severe intermittent wheezing. ( Bacharier, LB; Camera, LJ; Chinchilli, VM; Paul, IM; Phillips, BR; Rivera-Spoljaric, K; Strunk, RC; Taussig, LM; Zeiger, RS, 2009)
"Cough was assessed before and after the first cigarette of the day (received at 20 minutes) and throughout the day."	2.71	Effect of salbutamol on smoking related cough. ( Goustas, P; Morice, A; Mulrennan, S; Thompson, R; Wright, C, 2004)
"Cough is frequently the presenting symptom of bronchial asthma, although cough can result from a wide variety of other respiratory disease."	2.67	The effect of altering airway tone on the sensitivity of the cough reflex in normal volunteers. ( Adamson, DL; Choudry, NB; Fuller, RW; Smith, CA, 1991)
"Pretreatment with albuterol attenuated both the cough and the drop in FEV1."	2.66	Cough and wheezing from beclomethasone aerosol. ( Shim, C; Williams, MH, 1987)
"One trial on pertussis immunoglobulin reported a possible mean reduction of -3."	2.50	Symptomatic treatment of the cough in whooping cough. ( Bettiol, S; Harnden, A; Heneghan, CJ; Perera, R; Roberts, NW; Thompson, MJ; Wang, K, 2014)
" We summarized data relating to exacerbations and adverse events, particularly events related to COPD."	2.49	The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. ( Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP, 2013)
" To prove the safety and efficacy of the dosage form, a new HPLC method for analysis of salbutamol sulfate impurities was developed and validated."	1.56	Development and validation of a HPLC method for quantifica-tion of degradation impurities of salbutamol sulfate with following long-term stability studies in multicomponent cough syrup. ( Bezruk, I; Bunyatyan, V; Georgiyants, V; Gubar, S; Ivanauskas, L; Kovalenko, SM; Materiienko, A, 2020)
"Cough is one of the most common symptoms of asthma."	1.35	Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. ( Kontra, KM; Koskela, HO; Purokivi, MK; Taivainen, AH; Tukiainen, HO, 2008)
"All PRAE (laryngospasm, bronchospasm, oxygen desaturation [<95%], severe coughing) were recorded."	1.35	Salbutamol premedication in children with a recent respiratory tract infection. ( Erb, TO; Habre, W; Heaney, M; von Ungern-Sternberg, BS, 2009)
"No effects of treatment on cough frequency were demonstrated."	1.27	Night cough and general practice research. ( Howie, JG; Paxton, FM; Toop, LJ, 1986)

Research

Studies (87)

Timeframe	Studies, this research(%)	All Research%
pre-1990	15 (17.24)	18.7374
1990's	21 (24.14)	18.2507
2000's	23 (26.44)	29.6817
2010's	24 (27.59)	24.3611
2020's	4 (4.60)	2.80

Authors

Authors	Studies
Zaitsev, AA	1
Leshchenko, IV	1
Esaulova, NA	1
Viktorova, IA	1
Maddah, SA	1
Barzegari, A	1
Uhliariková, I	1
Šutovská, M	3
Barboríková, J	1
Molitorisová, M	1
Kim, HJ	1
Park, YI	1
Matulová, M	1
Lukavský, J	1
Hromadková, Z	1
Capek, P	3
Bezruk, I	1
Materiienko, A	1
Gubar, S	1
Bunyatyan, V	1
Kovalenko, SM	1
Georgiyants, V	1
Ivanauskas, L	1
Sauer, R	1
Griff, S	1
Blau, A	1
Franke, A	1
Mairinger, T	1
Grah, C	1
Koskela, HO	2
Lätti, AM	1
Purokivi, MK	2
Morjaria, JB	1
Rigby, AS	1
Morice, AH	1
Oduwole, O	1
Udoh, EE	1
Oyo-Ita, A	1
Meremikwu, MM	1
Bel, EH	1
Nurgozhin, TS	1
Guliaev, AE	1
Ermekbaeva, BA	1
Zhaugasheva, SK	1
Abuova, GT	1
An, ÉA	1
Ovchinnikov, AI	1
Paniakina, MA	1
Korostelev, SA	1
Mitiuk, AM	1
Zanasi, A	1
Lecchi, M	1
Del Forno, M	1
Fabbri, E	1
Mastroroberto, M	1
Mazzolini, M	1
Pisani, L	1
Pandolfi, P	1
Nava, S	1
Morselli-Labate, AM	1
Wang, K	2
Bettiol, S	3
Thompson, MJ	3
Roberts, NW	3
Perera, R	3
Heneghan, CJ	3
Harnden, A	3
Tagaya, E	1
Kondo, M	1
Kirishi, S	1
Kawagoe, M	1
Kubota, N	1
Tamaoki, J	1
Kocmálová, M	2
Fraňová, S	2
Pawlaczyk, I	2
Gancarz, R	2
Flores, P	1
Mendes, AL	1
Neto, AS	1
Waris, A	1
Macharia, M	1
Njeru, EK	1
Essajee, F	1
Fujimura, M	1
Rivera-Spoljaric, K	1
Chinchilli, VM	1
Camera, LJ	1
Zeiger, RS	1
Paul, IM	1
Phillips, BR	1
Taussig, LM	1
Strunk, RC	1
Bacharier, LB	1
von Ungern-Sternberg, BS	1
Habre, W	1
Erb, TO	1
Heaney, M	1
Cevik, Y	1
Onay, M	1
Akmaz, I	1
Sezigen, S	1
Mele, L	1
Sly, PD	1
Calogero, C	1
Bernardini, R	1
Novembre, E	1
Azzari, C	1
de Martino, M	1
Lombardi, E	1
Prabhu Shankar, S	1
Chandrashekharan, S	1
Bolmall, CS	1
Baliga, V	1
Radice, S	1
Milanesi, A	1
Antoniazzi, S	1
Perrone, V	1
Carnovale, C	1
Clementi, E	1
Maiello, N	1
Del Giudice, MM	1
Capristo, C	1
Decimo, F	1
Santaniello, F	1
Perrone, L	1
Boner, A	1
Sawada, S	1
Suehisa, H	1
Yamashita, M	1
Boskabady, M	2
Boskabady, MH	1
Zabihi, NA	1
Decramer, ML	1
Hanania, NA	1
Lötvall, JO	1
Yawn, BP	1
Lindsey, JK	1
Stevens, JW	1
Jones, B	1
Jackson, D	1
Agarwal, A	1
Azim, A	1
Ambesh, S	1
Bose, N	1
Dhiraj, S	1
Sahu, D	1
Singh, U	1
Chan, EY	1
Bridge, PD	3
Dundas, I	1
Pao, CS	1
Healy, MJ	2
McKenzie, SA	3
Li, SL	1
Mulrennan, S	1
Wright, C	1
Thompson, R	1
Goustas, P	1
Morice, A	1
Stephens, MM	1
Nashelsky, J	1
Hatch, RL	1
Bennett, WD	1
Almond, MA	1
Zeman, KL	1
Johnson, JG	1
Donohue, JF	1
Tomerak, AA	1
Vyas, H	1
Lakenpaul, M	1
McGlashan, JJ	1
McKean, M	1
Elkins, MR	1
Robinson, M	1
Rose, BR	1
Harbour, C	1
Moriarty, CP	1
Marks, GB	1
Belousova, EG	1
Xuan, W	1
Bye, PT	1
Lehmann, S	1
Bakke, PS	1
Eide, GE	1
Gulsvik, A	1
Beydon, N	1
M'buila, C	1
Bados, A	1
Peiffer, C	1
Bernard, A	1
Zaccaria, I	1
Denjean, A	1
Sabra, O	1
El-Bitar, M	1
Kontra, KM	1
Taivainen, AH	1
Tukiainen, HO	1
Peltola, H	1
Michelsson, K	1
Minette, A	1
Charpin, D	1
Beaupre, A	1
Orehek, J	1
Yahav, Y	1
Katznelson, D	1
Benzaray, S	1
Bolser, DC	1
DeGennaro, FC	1
O'Reilly, S	1
Hey, JA	1
Chapman, RW	1
Girard, V	1
Naline, E	1
Vilain, P	1
Emonds-Alt, X	1
Advenier, C	1
Laliberté, M	1
Sanfaçon, G	1
Blais, R	1
Hueston, WJ	2
Littenberg, B	1
Wheeler, M	1
Smith, DS	1
Hickner, JM	1
Shimizu, T	1
Mochizuki, H	1
Tokuyama, K	1
Morikawa, A	1
Chang, AB	1
Phelan, PD	1
Carlin, JB	1
Sawyer, SM	1
Robertson, CF	1
Kim, ES	1
Bishop, MJ	1
Dalphin, JC	1
Dubiez, A	1
Monnet, E	1
Gora, D	1
Westeel, V	1
Pernet, D	1
Polio, JC	1
Gibey, R	1
Laplante, JJ	1
Depierre, A	1
Bernard, DW	1
Goepp, JG	1
Duggan, AK	1
Serwint, JR	1
Rowe, PC	1
Agrawal, L	1
Beardsmore, CS	1
MacFadyen, UM	1
Jayaram, S	1
Desai, A	1
Linder, JA	1
Stafford, RS	1
Udezue, E	1
Mylonopoulou, M	1
Pavesio, D	1
Ponzone, A	1
Campbell, AH	1
O'Connell, JM	1
Wilson, F	1
Cohen, BM	1
Korppi, M	1
Laurikainen, K	1
Pietikäinen, M	1
Silvasti, M	3
Yuksel, B	1
Greenough, A	1
Frans, A	2
Garin, P	1
Van den Eeckhaudt, J	1
Smith, CA	1
Adamson, DL	1
Choudry, NB	1
Fuller, RW	1
Hoskyns, EW	1
Thomson, A	1
Decker, E	1
Hutchins, A	1
Simpson, H	1
Nichol, G	1
Nix, A	1
Barnes, PJ	1
Chung, KF	1
Van den Eeckhaut, J	1
Garlin, P	1
Russell, L	1
Shaw, NJ	1
Eden, OB	1
Pounsford, JC	1
Birch, MJ	1
Saunders, KB	1
Higenbottam, TW	1
Belcher, N	1
Rees, PJ	1
Karttunen, P	2
Tukiainen, H	2
Kolonen, S	1
Banerjee, DK	1
Lee, GS	1
Malik, SK	1
Daly, S	1
Toop, LJ	1
Howie, JG	1
Paxton, FM	1
Flygare, U	1
Korhonen, R	1
Korhonen, T	1
Majander, R	1
Seuri, M	1
Shim, C	1
Williams, MH	1

Clinical Trials (11)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Chart Review Assessing the Effects of Nebulised Hypertonic Saline on Respiratory-related Complications in Children and Young People With Neuromuscular Disease and Cerebral Palsy[NCT03623698]		24 participants (Actual)	Observational	2018-06-15	Completed
The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis[NCT00271310]	Phase 3	164 participants	Interventional	2000-09-30	Completed
The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis.[NCT00484263]	Phase 3	40 participants (Actual)	Interventional	2007-12-31	Completed
Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis[NCT01031706]		23 participants (Actual)	Interventional	2009-09-30	Completed
Nebulized Hypertonic Saline for Mechanically Ventilated Children[NCT01945944]	Phase 1/Phase 2	18 participants (Actual)	Interventional	2013-10-31	Completed
Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention[NCT04923880]		643 participants (Actual)	Interventional	2021-06-25	Active, not recruiting
Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis[NCT01094704]	Phase 1	16 participants (Actual)	Interventional	2009-11-30	Completed
Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.[NCT01952470]	Phase 2	32 participants (Actual)	Interventional	2013-10-31	Completed
The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial[NCT02914652]	Phase 4	96 participants (Actual)	Interventional	2016-10-15	Completed
Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258]		102 participants (Actual)	Observational	2015-09-30	Completed
Effect of Oral Procaterol on Chronic Persistent Cough Following Upper Respiratory Tract Infection: Double-Blind Randomized Placebo-Controlled Trial[NCT02349919]		74 participants (Anticipated)	Interventional	2015-03-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

%SpO2

Nocturnal oxygen saturation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of SpO2 (Mean)
Before Treatment	96.55
After Treatment	96.53

AHI

Nocturnal Apnoea Hipopnea index: total number of apnea events plus hypopnea events divided by the total number of minutes of actual sleep time and then multiplied by 60. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	8.53
After Treatment	1.38

Apnea Index (AI)

The number of apneas recorded during the study per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	4.87
After Treatment	0.40

FEV1/FVC %Predicted Rate of Decline

Rate of decline per year of Tiffenau index (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	97.37
After Treatment	98.89

FEV1% Predicted Rate of Decline

"Rate of decline of Forced Expiratory Volume in first second (FEV1) percentage of predicted.~Rate of decline is a measure of slope of FEV1 percentage predicted.~Baseline slope: [(FEV1% at baseline / FEV1% 12 months before treatment) - 1] * 100 After treatment slope: [(FEV1% 12 months after treatment / FEV1% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from the baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	-8.03
After Treatment	4.00

FVC% Predicted Rate of Decline

"Rate of decline of Forced Vital Capacity (FVC) percentage of predicted. Rate of decline is a measure of slope of FVC%.~Baseline slope: [(FVC% at baseline / FVC% 12 months before treatment) - 1] * 100 After treatment slope: [(FVC% 12 months after treatment / FVC% at baseline) - 1] * 100" (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	percentage of predicted (Median)
Before Treatment	-7.44
After Treatment	7.00

Nocturnal ODI

Oxygen desaturation index: Number of desaturations per hour of sleep (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Events per hour of sleep (Mean)
Before Treatment	4.26
After Treatment	3.32

Number of Hospitalsations Due to Respiratory Exacerbations

Number of respiratory exacerbations that required not planned hospitalisation (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Hospitalisations (Median)
Before Treatment	1
After Treatment	0

Peak Expiratory Flow (PEF)

Peak expiratory flow percentage of predicted (NCT03623698)
Timeframe: Change from baseline peak expiratory flow at 12 months after starting treatment with hypertonic saline

Intervention	percentage of predicted (Median)
Before Treatment	43.5
After Treatment	47

Score on the Ease of Airway Clearance From Parents or Legal Guardians

Measures ease of airway clearance through a 1-5 likert scale: 1) Very easy, 2) Easy, 3) Neither easy nor difficult, 4) Not easy, 5) Not at all easy. (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	score on a scale (Mean)
Before Treatment	4.21
After Treatment	2.13

Score on the Ease of Airway Clearance Pictorial Analogue Scale From Children and Young Adults as Participants

"Pictorial visual scale Facial Rating of perceived exertion Scale. Measures ease of airway clearance. Values range starting in 0 (Extremely easy) to 10 (Extremely hard), including 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Numbers are also associated with facial expressions." (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	score on a scale (Mean)
Before Treatment	6.45
After Treatment	2

TcPCO2

Nocturnal Transcutaneous Carbon Dioxide in kPa (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Kilopascal (kPa) (Mean)
Before Treatment	5.77
After Treatment	6.00

Change in Antibiotic Courses

Treatments due to respiratory exacerbations (NCT03623698)
Timeframe: Change from baseline (before treatment) and 12 months after treatment

Intervention	Courses of antibiotics (Median)
	Total courses of antibiotics	Courses of Oral antibiotics	Courses of intravenous antibiotics
After Treatment	1	1.00	0.00
Before Treatment	4	2.50	1.00

Parent's or Legal Guardian's Perception of Treatment

"Hypertonic saline treatment questionnaire for legal guardian. Measures the perception of overall usefulness of nebulised hypertonic saline through a likert scale: Very useful, useful, neither useful or not useful, not useful, not at all useful." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline

Intervention	Participants (Count of Participants)
	Very useful	useful	neither useful or not useful	not useful	not at all useful
Parent's or Legal Guardians	15	9	0	0	0

Participant's Perception of Treatment

"Questionnaire: Hypertonic saline treatment questionnaire. Perception of overall usefulness of nebulised hypertonic saline: Useful, Not useful, I don't know." (NCT03623698)
Timeframe: At 12 months after starting treatment with hypertonic saline

Intervention	Participants (Count of Participants)
	Useful	Not useful	I don't know
Children and Young People With Neuromuscular Disease	11	0	0

Change in Mucociliary Clearance Rate

"Average radio tracer clearance through 90 minutes (MCC90) is primary index of mucociliary clearance at each study.~Primary study outcome: is absolute change in MCC90 between baseline and at end of treatment (where MCC measured 8-12 hours after final dose of study drug) - reflects sustained impact on MCC" (NCT01031706)
Timeframe: Baseline versus after completion of 4 week treatment period

Intervention	percent clearance (Mean)
Hypertonic Saline	2.77
Placebo	-2.35

FEV1 (Spirometry) Change

Absolute change in % predicted FEV1 between baseline and after 4 weeks of treatment calculated (NCT01031706)
Timeframe: Baseline and after 4 weeks of treatment

Intervention	Percentage of predicted FEV1 (Mean)
Hypertonic Saline	3.38
Placebo	1.09

Atelectasis

"using chest x ray score. The score measures the amount of lung collapse (atelectasis) observed on a chest x-ray. For each of the 5 lung lobes, 1 point is given for linear atelectasis, 2 points for sub-segmental atelectasis and 3 points for lobar atelectasis. The range is 0-15 points, with higher scores reflecting more severe lung collapse." (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)

Intervention	units on a scale (Median)
Placebo	4.67
Hypertonic Saline	4

Change in Serum Sodium From Baseline

The baseline sodium was the last level measured prior to study initiation, typically within 24hrs of study initiation. The change in blood sodium level was calculated as the difference between the mean post-enrollment sodium level during ICU care and the sodium level at enrollment. (NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)

Intervention	mEq/L (Median)
Placebo	1
Hypertonic Saline	-1.5

Dead Space

in % of tidal volume, using parameters on mechanical ventilator. Dead space is a measure of how much of the lung is not able to move air into and out of the body. Higher levels of dead space reflect higher levels of lung dysfunction. (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)

Intervention	percentage of lung volume (Median)
Placebo	29
Hypertonic Saline	37

Duration of Mechanical Ventilation

(NCT01945944)
Timeframe: typically 4 days - 2 weeks

Intervention	hours (Median)
Placebo	129.5
Hypertonic Saline	208.1

Dynamic Compliance

measured in ml/cm H20/kg using parameters on mechanical ventilator (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)

Intervention	mL/kg/cm-H20 (Median)
Placebo	6.52
Hypertonic Saline	4.47

Hospital Length of Stay

(NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)

Intervention	days (Median)
Placebo	15
Hypertonic Saline	17

ICU Length of Stay

(NCT01945944)
Timeframe: during hospitalization (typically 4 days - 2 weeks)

Intervention	days (Median)
Placebo	8
Hypertonic Saline	12

Oxygenation

SaO2/FiO2. This is a measure of how will the lungs are providing oxygen to the body. Higher ratios reflect better lung function. (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)

Intervention	ratio (Median)
Placebo	239
Hypertonic Saline	188

Wheezing

as dichotomous outcome (yes/no) following drug administration (NCT01945944)
Timeframe: during mechanical ventilation (typically 4 days - 2 weeks)

Intervention	percentage of drug doses w/ wheezing (Number)
Placebo	3
Hypertonic Saline	1

Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline)

Duration of action of hypertonic saline as determined by measurements of mucociliary clearance/cough clearance 4 hours post dose. (NCT01094704)
Timeframe: 1-4 hours post-dose

Intervention	Absolute % change (Mean)
Hypertonic Saline - 1 Hour	5.9
Hypertonic Saline - 4 Hours	6.7

Breathlessness, Cough and Sputum Scale (BCSS) - Exacerbations

"Self-reported symptom severity, used as a daily patient diary. The BCSS is a 12 point self-reported symptom severity score, consisting of 3 sections concerning how much difficulty the subject is having with breathing; subjective cough symptoms and trouble caused by sputum, each scoring between 0-4, combining to a total score of 0-12 (higher=worse). This scale is validated for daily use in Chronic Obstructive Pulmonary Disease (COPD)(21).~An exacerbation was defined as an increase in BCSS>1 with ≥5 days preceding stability." (NCT01952470)
Timeframe: Daily up to 3 months.

Intervention	Exacerbations (Mean)
	Intervention phase	Follow-up phase
Dornase Alfa	0.94	2.64
Isotonic Saline	1.07	3.62

BronkoTest (Sputum Colour) - Purulent Sputum Days

Sputum colour chart. Sputum colour has been shown to correlate with physiological infection in other chronic lung disease groups(22). (NCT01952470)
Timeframe: Daily up to 3 months.

Intervention	days (Median)
	Intervention phase	Follow-up phase
Dornase Alfa	11.50	4.50
Isotonic Saline	8.50	6.00

C-reactive Protein (CRP)

An inflammatory marker measured with routine blood tests on admission with LRTI. Taken during inpatient (IP) stay and routinely on outpatient (OP) follow-up. Existing / available data only will be used - no extra routine bloods will be taken on account of study inclusion. (NCT01952470)
Timeframe: 1 month, 3 months.

Intervention	mg/L (change) (Median)
	1 month	3 months
Dornase Alfa	1.00	12
Isotonic Saline	2.50	1.00

Forced Expiratory Ratio (FER)

FER represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Ratio (Mean)
	1 month	3 months
Dornase Alfa	66.33	62.79
Isotonic Saline	70.87	70.27

Forced Expiratory Volume in 1 Second (FEV1) Liters

FEV1 is the maximal amount of air you can forcefully exhale in one second. (NCT01952470)
Timeframe: 1 month, 3 months.

Intervention	Liters (L) - change (Mean)
	FEV1 L 1 month	FEV1 L 3 months
Dornase Alfa	2.11	1.91
Isotonic Saline	1.76	1.78

Forced Expiratory Volume in 1 Second (FEV1) Percent.

FEV1 is the maximal amount of air you can forcefully exhale in one second. (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Percent (%) (Mean)
	1 month	3 months
Dornase Alfa	69.33	63.00
Isotonic Saline	58.33	57.60

Forced Vital Capacity (FVC) Liters

Forced vital Capacity (FVC) is a measure of the amount of air someone can forcibly expel out of the lungs after taking a breath to fill the lungs as much as possible. (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Liters (L) (Mean)
	1 month	3 months
Dornase Alfa	3.21	2.96
Isotonic Saline	2.46	2.50

Forced Vital Capacity (FVC) Percent

Intervention	Percent (%) (Mean)
	1 month	3 months
Dornase Alfa	79.40	74.41
Isotonic Saline	62.07	63.73

Functional Residual Capacity (FRC)

Volume of air remaining in the lungs after normal expiration. (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Liters (L) (Mean)
	1 month	3 months
Dornase Alfa	2.03	2.22
Isotonic Saline	1.80	1.78

Inpatient Days

Number of days spent in the acute inpatient setting. (NCT01952470)
Timeframe: Across study period (3 months).

Intervention	Days (Mean)
	All cause - intervention	All cause - follow-up	Respiratory - intervention	Respiratory - follow-up
Dornase Alfa	8.67	8.09	9.20	9.83
Isotonic Saline	12.50	11.38	21.50	14.33

Leicester Cough Questionnaire (LCQ) - Change

Cough specific quality of life questionnaire. The LCQ is a 19-question tool, validated in chronic lung disease other than lung transplant(19). Scale 1-7 for physical, psychological, social. Combined score of 3-21 for total. Lower=worse. (NCT01952470)
Timeframe: 1 month, 3 months.

Intervention	score on a scale (Mean)
	Physical 1 month	Physical 3 months	Psychological 1 month	Psychological 3 months	Social 1 month	Social 3 months	Total 1 month	Total 3 months
Dornase Alfa	5.73	5.56	6.32	6.03	6.33	6.12	17.26	17.70
Isotonic Saline	5.12	5.69	5.87	6.05	5.75	6.07	16.72	17.81

Lung Clearance Index 2% (LCI2%)

"A measure of ventilation inhomogeneity as measured during multiple breath washout (MBW) of inert tracer gases. It has been shown that this test is a potentially more sensitive measure of peripheral airway obstruction than regular spirometry in short term (4 week) mucolytic interventional studies in pediatric Cystic Fibrosis (CF)(17-18). This test would be performed within the respiratory physiology lung function laboratory on site at all assessment points, by an assessor who is blinded to group allocation for follow up data collection.~Conventionally used primary endpoints in this population, such as regular spirometry(3), may be unable to detect between group differences without large sample sizes and long treatment durations. Based on current evidence from non-lung transplant populations, LCI has been able to show short-term change, whereas regular spirometry has not shown change(17-18)." (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Index (change) (Mean)
	1 month	3 months
Dornase Alfa	10.68	10.09
Isotonic Saline	11.65	11.19

Multiple Breath Washout (MBW)

"Multiple breath washout is a sensitive measure of respiratory function performed with the subject in a seated position, breathing a fixed tidal volume (1L) of inert gas (nitrogen) from functional residual capacity (FRC) via mouthpiece.~Two common outcomes of MBW are Sacin, a measure of gas mixing at the diffusion front, or acinar entrance in the airways, and Scond, in the proximal, conductive zones. An increase in either Sacin or Scond represents an increase in ventilation heterogeneity (deterioration). Both increase with age, normal values are non-zero between 0-0.25(Sacin) and 0-0.1(Scond)." (NCT01952470)
Timeframe: 1 month, 3 months

Intervention	Gas mixing index (Sacin / Scond) (Mean)
	Sacin 1 month	Sacin 3 months	Scond 1 month	Scond 3 months
Dornase Alfa	0.348	0.354	0.045	0.033
Isotonic Saline	0.383	0.356	0.026	0.021

Number of Hospitalizations

Number of admissions to the acute setting. (NCT01952470)
Timeframe: Over study period (3 months).

Intervention	Hospitalizations (Number)
	All cause - intervention	All cause - follow-up	Respiratory - intervention	Respiratory - follow-up
Dornase Alfa	8	12	7	6
Isotonic Saline	4	8	2	6

Oral, Inhaled or Intravenous Antibiotic (IVAB) Days.

Antibiotic use for the treatment of lower respiratory tract infections (LRTI) only. (NCT01952470)
Timeframe: Over study period (3 months).

Intervention	Days (Median)
	Intervention phase	Follow-up phase
Dornase Alfa	23.50	14.00
Isotonic Saline	25.00	10.50

St. George's Respiratory Questionnaire (SGRQ) - Change

"The SGRQ is a 2-part questionnaire, validated in chronic lung disease other than lung transplant(20).~50 items, 76 weighted responses. Scores range 0-100, higher=worse." (NCT01952470)
Timeframe: 1 month, 3 months.

Intervention	units on a scale (Mean)
	Symptom 1 month	Symptom 3 months	Activity 1 month	Activity 3 months	Impact 1 month	Impact 3 months	Total 1 month	Total 3 months
Dornase Alfa	55.65	48.52	40.82	53.18	20.59	25.96	32.50	37.97
Isotonic Saline	61.93	51.47	57.38	53.81	30.72	33.90	43.58	40.81

Reviews

11 reviews available for albuterol and Cough

Article	Year
Honey for acute cough in children. The Cochrane database of systematic reviews, 2018, 04-10, Volume: 4 Topics: Adolescent; Albuterol; Antitussive Agents; Apitherapy; Bromelains; Bronchodilator Agents; Child; Chi	2018
Drugs for cough. The Medical letter on drugs and therapeutics, 2018, Dec-17, Volume: 60, Issue:1562 Topics: Albuterol; Antitussive Agents; Codeine; Cough; Dextromethorphan; Humans	2018
Clinical Practice. Mild asthma. The New England journal of medicine, 2013, Aug-08, Volume: 369, Issue:6 Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Algorithms; Anti-Asthmatic Agents;	2013
Symptomatic treatment of the cough in whooping cough. The Cochrane database of systematic reviews, 2014, Sep-22, Issue:9 Topics: Acetates; Adolescent; Adult; Albuterol; Anti-Inflammatory Agents; Bordetella pertussis; Child; Cough	2014
[Causes of prolonged and chronic cough]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:6 Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr	2008
Symptomatic treatment of the cough in whooping cough. The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1 Topics: Adult; Albuterol; Anti-Inflammatory Agents; Child; Cough; Dexamethasone; Diphenhydramine; Histamine	2010
Symptomatic treatment of the cough in whooping cough. The Cochrane database of systematic reviews, 2012, May-16, Issue:5 Topics: Adult; Albuterol; Anti-Inflammatory Agents; Bordetella pertussis; Child; Cough; Dexamethasone; Diphe	2012
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease, 2013, Volume: 8 Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Blood Glucose; Cough; Ethanolamines; Formoterol Fuma	2013
Clinical inquiries. Do inhaled beta-agonists control cough in URIs or acute bronchitis? The Journal of family practice, 2004, Volume: 53, Issue:8 Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Bronchitis; C	2004
Inhaled beta2-agonists for treating non-specific chronic cough in children. The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3 Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Child; Chronic Disease; Cough; Huma	2005
[Isolated cough and bronchial asthma]. Revue de pneumologie clinique, 1991, Volume: 47, Issue:2 Topics: Adolescent; Adult; Aged; Albuterol; Asthma; Beclomethasone; Bronchial Provocation Tests; Chronic Dis	1991

Trials

37 trials available for albuterol and Cough

Article	Year
[Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch Terapevticheskii arkhiv, 2023, Apr-26, Volume: 95, Issue:3 Topics: Acute Disease; Adult; Albuterol; Ambroxol; Bromhexine; Bronchitis; Cough; Drug Combinations; Expecto	2023
The Effect of Albuterol Spray on Hypoxia and Bronchospasm in Patients with Chronic Obstructive Pulmonary Disease (COPD) under General Anesthesia: A bouble-Blind Randomized Clinical Trial. Ethiopian journal of health sciences, 2023, Volume: 33, Issue:3 Topics: Adult; Albuterol; Anesthesia, General; Bronchial Spasm; Bronchodilator Agents; Cough; Double-Blind M	2023
Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma? The European respiratory journal, 2017, Volume: 50, Issue:6 Topics: Adrenergic beta-2 Receptor Agonists; Adult; Age Distribution; Aged; Albuterol; Anti-Asthmatic Agents	2017
[Results of international multicentre non-interventional clinical study of the effectiveness and safety of ascoril expectorant for the treatment of cough in Kazakhstan and Uzbekistan]. Klinicheskaia meditsina, 2013, Volume: 91, Issue:6 Topics: Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Bromhexine; Child, Preschoo	2013
[Therapeutic modalities for the management of cough associated with acute respiratory viral infection, effective in an otolaryngologist's practice]. Vestnik otorinolaringologii, 2014, Issue:2 Topics: Acute Disease; Adult; Albuterol; Ambroxol; Bromhexine; Bronchodilator Agents; Cough; Drug Combinatio	2014
A randomized, placebo-controlled, double-blind trial on the management of post-infective cough by inhaled ipratropium and salbutamol administered in combination. Pulmonary pharmacology & therapeutics, 2014, Volume: 29, Issue:2 Topics: Administration, Inhalation; Adult; Aged; Albuterol; Bronchodilator Agents; Cough; Double-Blind Metho	2014
Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma. The Journal of asthma : official journal of the Association for the Care of Asthma, 2015, Volume: 52, Issue:5 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Albuterol; Androstadienes; Asthma; Bronc	2015
A randomized trial of nebulized 3% hypertonic saline with salbutamol in the treatment of acute bronchiolitis in hospitalized infants. Pediatric pulmonology, 2016, Volume: 51, Issue:4 Topics: Administration, Inhalation; Albuterol; Bronchiolitis; Bronchodilator Agents; Child, Hospitalized; Co	2016
RANDOMISED DOUBLE BLIND STUDY TO COMPARE EFFECTIVENESS OF HONEY, SALBUTAMOL AND PLACEBO IN TREATMENT OF COUGH IN CHILDREN WITH COMMON COLD. East African medical journal, 2014, Volume: 91, Issue:2 Topics: Albuterol; Bronchodilator Agents; Child; Common Cold; Cough; Double-Blind Method; Female; Honey; Hum	2014
Signs and symptoms that precede wheezing in children with a pattern of moderate-to-severe intermittent wheezing. The Journal of pediatrics, 2009, Volume: 154, Issue:6 Topics: Acetates; Adult; Albuterol; Anti-Asthmatic Agents; Asthenia; Bronchodilator Agents; Budesonide; Caus	2009
Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. Journal of the Indian Medical Association, 2010, Volume: 108, Issue:5 Topics: Adolescent; Adult; Aged; Albuterol; Bromhexine; Cough; Double-Blind Method; Drug Combinations; Expec	2010
Inhalation of corticosteroid and β-agonist for persistent cough following pulmonary resection. General thoracic and cardiovascular surgery, 2012, Volume: 60, Issue:5 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Albu	2012
Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2003, Volume: 50, Issue:3 Topics: Adolescent; Adult; Albuterol; Beclomethasone; Cough; Cromolyn Sodium; Female; Fentanyl; Histamine Re	2003
Repeatability of airway resistance measurements made using the interrupter technique. Thorax, 2003, Volume: 58, Issue:4 Topics: Airway Resistance; Albuterol; Bronchial Provocation Tests; Bronchodilator Agents; Child; Child, Pres	2003
[The comparative effects of aminophylline and salbutamol on the treatment of infant allergic cough]. Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 2003, Volume: 15, Issue:7 Topics: Albuterol; Aminophylline; Asthma; Child; Child, Preschool; Cough; Humans; Treatment Outcome	2003
Effect of salbutamol on smoking related cough. Pulmonary pharmacology & therapeutics, 2004, Volume: 17, Issue:3 Topics: Adult; Albuterol; Antitussive Agents; Cough; Cross-Over Studies; Double-Blind Method; Female; Humans	2004
Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulmonary pharmacology & therapeutics, 2006, Volume: 19, Issue:2 Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Bronchitis, Chronic; Cough; Cross-Over Studies; Do	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Absenteeism; Administration, Inhalation; Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Bronch	2006
Deep-inspiration induced bronchoconstriction: a mechanism for beclomethasone aerosol intolerance. European journal of respiratory diseases, 1983, Volume: 64, Issue:7 Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Beclomethasone; Bronchial Spasm; Cough; Humans; Prem	1983
Albuterol delivered by metered-dose inhaler to treat acute bronchitis. The Journal of family practice, 1994, Volume: 39, Issue:5 Topics: Acute Disease; Adult; Aerosols; Albuterol; Bronchitis; Combined Modality Therapy; Cough; Double-Blin	1994
A randomized controlled trial of oral albuterol in acute cough. The Journal of family practice, 1996, Volume: 42, Issue:1 Topics: Acute Disease; Administration, Oral; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Ambulatory Ca	1996
A randomised, placebo controlled trial of inhaled salbutamol and beclomethasone for recurrent cough. Archives of disease in childhood, 1998, Volume: 79, Issue:1 Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Albuterol; Beclomethasone; Bronchi	1998
Cough during emergence from isoflurane anesthesia. Anesthesia and analgesia, 1998, Volume: 87, Issue:5 Topics: Albuterol; Anesthesia, Inhalation; Anesthetics, Inhalation; Bronchodilator Agents; Cough; Female; Hu	1998
Is oral albuterol effective for acute cough in non-asthmatic children? Acta paediatrica (Oslo, Norway : 1992), 1999, Volume: 88, Issue:4 Topics: Acute Disease; Administration, Oral; Albuterol; Child; Cough; Double-Blind Method; Humans; Survival	1999
Efficacy and safety of Ascoril expectorant and other cough formula in the treatment of cough management in paediatric and adult patients--a randomised double-blind comparative trial. Journal of the Indian Medical Association, 2000, Volume: 98, Issue:2 Topics: Adolescent; Adult; Albuterol; Ammonium Chloride; Bromhexine; Child; Child, Preschool; Citrates; Coug	2000
Salbutamol and pertussis. Lancet (London, England), 1977, Jan-15, Volume: 1, Issue:8003 Topics: Albuterol; Child, Preschool; Cough; Drug Evaluation; Humans; Infant; Placebos; Whooping Cough	1977
Antitussives in the treatment of acute transient cough in children. Acta paediatrica Scandinavica, 1991, Volume: 80, Issue:10 Topics: Acute Disease; Albuterol; Child; Child, Preschool; Cough; Dextromethorphan; Double-Blind Method; Fem	1991
Effect of nebulized salbutamol in preterm infants during the first year of life. The European respiratory journal, 1991, Volume: 4, Issue:9 Topics: Aerosols; Albuterol; Cough; Female; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Lu	1991
The effect of altering airway tone on the sensitivity of the cough reflex in normal volunteers. The European respiratory journal, 1991, Volume: 4, Issue:9 Topics: Adult; Albuterol; Bronchial Provocation Tests; Bronchodilator Agents; Capsaicin; Cough; Female; Huma	1991
A comparison of albuterol and erythromycin for the treatment of acute bronchitis. The Journal of family practice, 1991, Volume: 33, Issue:5 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Albuterol; Bronchitis; Cough; Double-B	1991
Effect of controlled release salbutamol on nocturnal cough in asthma. Archives of disease in childhood, 1991, Volume: 66, Issue:10 Topics: Adolescent; Albuterol; Asthma; Child; Cough; Delayed-Action Preparations; Double-Blind Method; Femal	1991
Prostaglandin F2 alpha enhancement of capsaicin induced cough in man: modulation by beta 2 adrenergic and anticholinergic drugs. Thorax, 1990, Volume: 45, Issue:9 Topics: Administration, Inhalation; Adult; Albuterol; Capsaicin; Cough; Dinoprost; Dose-Response Relationshi	1990
Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects. Thorax, 1985, Volume: 40, Issue:9 Topics: Aerosols; Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Citrates; Citric Acid; Cough;	1985
Effects of pholcodine and salbutamol on citric acid induced cough in normal subjects. Thorax, 1986, Volume: 41, Issue:1 Topics: Albuterol; Citrates; Citric Acid; Clinical Trials as Topic; Codeine; Cough; Double-Blind Method; Hum	1986
Antitussive effect of dextromethorphan and dextromethorphan-salbutamol combination in healthy volunteers with artificially induced cough. Respiration; international review of thoracic diseases, 1987, Volume: 52, Issue:1 Topics: Adult; Albuterol; Antitussive Agents; Citrates; Citric Acid; Cough; Dextromethorphan; Double-Blind M	1987
The treatment of acute transient cough: a placebo-controlled comparison of dextromethorphan and dextromethorphan-beta 2-sympathomimetic combination. European journal of respiratory diseases, 1986, Volume: 69, Issue:2 Topics: Acute Disease; Adult; Albuterol; Cough; Dextromethorphan; Double-Blind Method; Drug Combinations; Dy	1986
Cough and wheezing from beclomethasone aerosol. Chest, 1987, Volume: 91, Issue:2 Topics: Aerosols; Albuterol; Asthma; Beclomethasone; Cough; Double-Blind Method; Forced Expiratory Volume; H	1987

Other Studies

39 other studies available for albuterol and Cough

Article	Year
Structural characteristics and biological effects of exopolysaccharide produced by cyanobacterium Nostoc sp. International journal of biological macromolecules, 2020, Oct-01, Volume: 160 Topics: Albuterol; Animals; Biopolymers; Bronchodilator Agents; Cell Line; Codeine; Cough; Cyanobacteria; Cy	2020
Development and validation of a HPLC method for quantifica-tion of degradation impurities of salbutamol sulfate with following long-term stability studies in multicomponent cough syrup. Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2020,Winter, Volume: 69, Issue:5-6 Topics: Albuterol; Chromatography, High Pressure Liquid; Cough; Humans; Prospective Studies; Sulfates	2020
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia diagnosed by transbronchial lung cryobiopsy: a case report. Journal of medical case reports, 2017, Apr-07, Volume: 11, Issue:1 Topics: Aged; Albuterol; Anti-Inflammatory Agents; Biopsy; Bronchodilator Agents; Budesonide; Cough; Cryosur	2017
Long-term prognosis of chronic cough: a prospective, observational cohort study. BMC pulmonary medicine, 2017, Nov-21, Volume: 17, Issue:1 Topics: Aged; Albuterol; Asthma; Bronchial Provocation Tests; Chronic Disease; Comorbidity; Cough; Female; F	2017
Chemical and pharmacological profiles of Echinacea complex. International journal of biological macromolecules, 2015, Volume: 79 Topics: Albuterol; Animals; Antitussive Agents; Bronchodilator Agents; Chromatography, High Pressure Liquid;	2015
Salbutamol premedication in children with a recent respiratory tract infection. Paediatric anaesthesia, 2009, Volume: 19, Issue:11 Topics: Adolescent; Adrenergic beta-Agonists; Albuterol; Bronchial Spasm; Child; Child, Preschool; Cough; Fe	2009
Mass casualties from acute inhalation of chlorine gas. Southern medical journal, 2009, Volume: 102, Issue:12 Topics: Acute Disease; Administration, Inhalation; Adult; Albuterol; Bronchodilator Agents; Budesonide; Chem	2009
Assessment and validation of bronchodilation using the interrupter technique in preschool children. Pediatric pulmonology, 2010, Volume: 45, Issue:7 Topics: Airway Resistance; Albuterol; Asthma; Bronchi; Bronchodilator Agents; Child; Child, Preschool; Cough	2010
A case of haemorrhagic cystitis by inhaled salbutamol and salmeterol. European journal of clinical pharmacology, 2011, Volume: 67, Issue:11 Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; As	2011
Severe allergic reaction to lactulose in a child with milk allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011, Volume: 107, Issue:1 Topics: Albuterol; Anti-Allergic Agents; Cetirizine; Cheese; Child, Preschool; Cough; Humans; Immunoglobulin	2011
Characterization and biological activity of Solidago canadensis complex. International journal of biological macromolecules, 2013, Volume: 52 Topics: Airway Resistance; Albuterol; Animals; Antitussive Agents; Bronchodilator Agents; Codeine; Cough; Do	2013
The effect of chemical warfare on respiratory symptoms, pulmonary function tests and their reversibility 23-25 years after exposure. Toxicology and industrial health, 2015, Volume: 31, Issue:1 Topics: Adult; Albuterol; Bronchodilator Agents; Case-Control Studies; Chemical Warfare Agents; Cough; Human	2015
Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing. Statistics in medicine, 2002, Oct-30, Volume: 21, Issue:20 Topics: Adrenergic beta-Agonists; Albuterol; Capsaicin; Cough; Cross-Over Studies; Domperidone; Dopamine Ant	2002
Pain relief in those recovering from chemical dependency. American family physician, 2004, Nov-15, Volume: 70, Issue:10 Topics: Administration, Inhalation; Albuterol; Anti-Inflammatory Agents, Non-Steroidal; Bronchodilator Agent	2004
Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respiratory medicine, 2007, Volume: 101, Issue:6 Topics: Adrenergic beta-Agonists; Age Factors; Aged; Albuterol; Body Mass Index; Bronchoconstriction; Bronch	2007
Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respiratory medicine, 2007, Volume: 101, Issue:6 Topics: Adrenergic beta-Agonists; Age Factors; Aged; Albuterol; Body Mass Index; Bronchoconstriction; Bronch	2007
Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respiratory medicine, 2007, Volume: 101, Issue:6 Topics: Adrenergic beta-Agonists; Age Factors; Aged; Albuterol; Body Mass Index; Bronchoconstriction; Bronch	2007
Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respiratory medicine, 2007, Volume: 101, Issue:6 Topics: Adrenergic beta-Agonists; Age Factors; Aged; Albuterol; Body Mass Index; Bronchoconstriction; Bronch	2007
Interrupter resistance short-term repeatability and bronchodilator response in preschool children. Respiratory medicine, 2007, Volume: 101, Issue:12 Topics: Albuterol; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchodilator Agents; Child;	2007
The role of beta-2 agonists in foreign body aspiration. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2009, Volume: 266, Issue:4 Topics: Adrenergic beta-Agonists; Albuterol; Bronchi; Bronchoscopy; Child, Preschool; Cough; Female; Foreign	2009
Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2008, Volume: 38, Issue:7 Topics: Adult; Albuterol; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Bronchodilator Agents; C	2008
Efficacy of salbutamol in treatment of infant pertussis demonstrated by sound spectrum analysis. Lancet (London, England), 1982, Feb-06, Volume: 1, Issue:8267 Topics: Albuterol; Cough; Drug Evaluation; Humans; Infant; Sound Spectrography; Whooping Cough	1982
Clinical effects of mucolytics associated with bronchodilators in treating exacerbation of chronic bronchitis in coal miners. Revue de l'Institut d'hygiene des mines, 1982, Volume: 37, Issue:2 Topics: Acetylcysteine; Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Bronchitis; Cough; Drug Therap	1982
Persistent cough a forme-fruste of asthma. European journal of respiratory diseases, 1982, Volume: 63, Issue:1 Topics: Adolescent; Aerosols; Albuterol; Asthma; Bronchial Spasm; Child; Child, Preschool; Cough; Eosinophil	1982
Pharmacological studies of allergic cough in the guinea pig. European journal of pharmacology, 1995, Apr-24, Volume: 277, Issue:2-3 Topics: Administration, Oral; Aerosols; Albuterol; Analysis of Variance; Animals; Antitussive Agents; Capsai	1995
Effect of the two tachykinin antagonists, SR 48968 and SR 140333, on cough induced by citric acid in the unanaesthetized guinea pig. The European respiratory journal, 1995, Volume: 8, Issue:7 Topics: Administration, Inhalation; Aerosols; Albuterol; Animals; Antitussive Agents; Benzamides; Bronchocon	1995
Acute pulmonary toxicity linked to use of a leather protector. Annals of emergency medicine, 1995, Volume: 25, Issue:6 Topics: Adolescent; Adult; Albuterol; Child; Cough; Dyspnea; Female; Household Products; Humans; Male; Oxyge	1995
Oral albuterol for acute cough. The Journal of family practice, 1996, Volume: 42, Issue:2 Topics: Acute Disease; Administration, Oral; Adrenergic beta-Agonists; Adult; Albuterol; Cough; Double-Blind	1996
Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma. Thorax, 1996, Volume: 51, Issue:3 Topics: Acetates; Albuterol; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodilator	1996
Prevalence of asthma and respiratory symptoms in dairy farmers in the French province of the Doubs. American journal of respiratory and critical care medicine, 1998, Volume: 158, Issue:5 Pt 1 Topics: Adult; Age Factors; Albuterol; Allergens; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease	1998
Respiratory function in childhood following repair of oesophageal atresia and tracheoesophageal fistula. Archives of disease in childhood, 1999, Volume: 81, Issue:5 Topics: Albuterol; Bronchodilator Agents; Child; Cough; Deglutition Disorders; Esophageal Atresia; Female; F	1999
Airway resistance and atopy in preschool children with wheeze and cough. The European respiratory journal, 2000, Volume: 15, Issue:5 Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child, Preschool; Cough; Female; Humans	2000
The diagnosis and treatment of cough. The New England journal of medicine, 2001, Apr-05, Volume: 344, Issue:14 Topics: Acute Disease; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchitis; Common Cold; Cough; Diagnost	2001
Lidocaine inhalation for cough suppression. The American journal of emergency medicine, 2001, Volume: 19, Issue:3 Topics: Administration, Inhalation; Adult; Aged; Albuterol; Anesthetics, Local; Antitussive Agents; Asthma;	2001
Bronchodilator responsiveness and atopy in 5-10-yr-old coughers. The European respiratory journal, 2001, Volume: 18, Issue:6 Topics: Airway Resistance; Albuterol; Asthma; Bronchodilator Agents; Child; Child, Preschool; Cough; Cross-S	2001
The effect of chest physiotherapy upon the FEV1 in chronic bronchitis. The Medical journal of Australia, 1975, Jan-11, Volume: 1, Issue:2 Topics: Aged; Albuterol; Bronchitis; Chronic Disease; Cough; Drainage; Humans; Middle Aged; Percussion; Phys	1975
Maximum voluntary cough ratios reflect antitussive activity of inhaled albuterol. New Jersey medicine : the journal of the Medical Society of New Jersey, 1992, Volume: 89, Issue:8 Topics: Administration, Inhalation; Adult; Aged; Albuterol; Asthma; Cough; Female; Humans; Male; Maximal Exp	1992
Isolated cough which responds to inhaled salbutamol and beclomethasone dipropionate. The European respiratory journal, 1990, Volume: 3, Issue:2 Topics: Albuterol; Beclomethasone; Cough; Humans	1990
Efficacy of salbutamol in chronic cough in childhood leukaemia. Lancet (London, England), 1989, Mar-04, Volume: 1, Issue:8636 Topics: Albuterol; Child; Chronic Disease; Cough; Drug Evaluation; Humans; Pilot Projects; Precursor Cell Ly	1989
Anticholinergics and cough. Postgraduate medical journal, 1987, Volume: 63 Suppl 1 Topics: Administration, Inhalation; Administration, Oral; Albuterol; Bronchi; Cough; Fenoterol; Forced Expir	1987
Underdiagnosis of asthma in the elderly. British journal of diseases of the chest, 1987, Volume: 81, Issue:1 Topics: Aged; Aged, 80 and over; Albuterol; Asthma; Cough; Humans; Respiratory Function Tests	1987
Night cough and general practice research. The Journal of the Royal College of General Practitioners, 1986, Volume: 36, Issue:283 Topics: Albuterol; Child; Child, Preschool; Cough; Humans; Hypersensitivity, Immediate; Prospective Studies;	1986

chemdatabank.com